Press releases
Press releases are available from 1999, when MVI was established as a program at PATH, to the present.
2013 | 2012 | 2011 | 2010 | 2009 | Archived (2008–1999)
- RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
9 November 2012 - PATH Malaria Vaccine Initiative (MVI) creates new central “reference” lab, standardizing ability to measure performance of malaria vaccine formulations
20 August 2012 - PATH Malaria Vaccine Initiative and University of Oxford enter into agreement to conduct clinical trial of malaria vaccine prime-boost approach
16 August 2012 - PATH Malaria Vaccine Initiative names eminent malaria scientists and vaccinologists to advisory council
14 August 2012 - PATH Malaria Vaccine Initiative announces new leader
1 March 2012
- Advancing the development of a malaria transmission-blocking vaccine
6 December 2011 - First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children aged 5 to 17 months
18 October 2011 - PATH Malaria Vaccine Initiative to collaborate with GlaxoSmithKline and Crucell in development of second-generation malaria vaccine
7 June 2011 - MVI welcomes USAID head's appeal for new technologies for malaria
17 February 2011 - PATH Malaria Vaccine Initiative partners with Tulane University and India's Gennova Biopharmaceuticals to push development of transmission-blocking vaccine
15 February 2011
- The PATH Malaria Vaccine Initiative, Merck and NYU Langone Medical Center collaborate to research potential malaria vaccine
14 December 2010 - Malaria vaccine experts eye prime-boost approaches
3 November 2010 - Scientists to report on early data toward dramatically increasing the effectiveness of future malaria vaccines
3 November 2010 (41 KB PDF) - International Malaria Vaccines for the World Conference to showcase scientific push for “next generation” products
28 September 2010 (157 KB PDF) - An expert panel of African scientists will discuss the status of the world's most advanced malaria vaccine candidate at the Malaria Vaccines for the World conference
28 September 2010 (22 KB PDF) - Researchers, health experts, from five African countries convene to support advocacy for malaria vaccines
14 July 2010 (35 KB PDF) - The PATH Malaria Vaccine Initiative congratulates GlaxoSmithKline Biologicals and Crucell on new malaria vaccine collaboration
6 April, 2010 - Roll Back Malaria report confirms aid for malaria is working but predictable long-term funding is essential to achieve Millennium Development Goals
18 March 2010 (232 KB PDF) - PATH welcomes positive steps on price, donations for GlaxoSmithKline's RTS,S malaria vaccine candidate
20 January 2010 (34 KB PDF) - First steps taken toward the development of a malaria transmission-blocking vaccine
15 January 2010 (41 KB PDF)
- Scientists to discuss transmission-blocking vaccines and their role in malaria eradication
17 November 2009 (24 KB PDF) - World's largest malaria vaccine trial now underway in seven African countries
3 November, 2009 - PATH Malaria Vaccine Initiative shares strategy for developing "next-generation" malaria vaccines
2 November 2009 - MVI and Crucell announce collaboration to test new adenovirus-based malaria vaccine approach
29 July 2009 (63 KB PDF) - Phase 3 malaria vaccine trial begins—final testing of RTS,S
27 May 2009 - Phase 1 trial of whole-parasite malaria vaccine to begin
23 April 2009 (49 KB PDF)
- New collaboration builds on recent malaria antigen discovery
26 February 2009 (20 KB PDF)
